Zydus bags USFDA product approval for Levofloxacin
DSIJ Intelligence / 02 Jun 2017
The company received the USFDA approval for Levofloxacin injection, usually used for the treatment of bacterial infections.
Zydus’ manufacturing unit at Moraiya in Ahmedabad received its first product approval after its successful USFDA audit, triggering Cadila Healthcare by 7.1 per cent on June 2, 2017, to its all time high of Rs 504.80 on the bourses.
The company received the USFDA approval for Levofloxacin injection, usually used for the treatment of bacterial infections.
Zydus has more than 115 approvals pending with the US drug regulator, along with over 300 filed ANDAs since the beginning of the filing process in FY04.
The stock had hit its all time high of Rs 504.80 in intraday trade, and an intraday low of Rs 473.55 on the bourses on June 2, 2017.
At 01:00 hrs IST, the stock was trading at Rs 494.45, up by 5 per cent on the BSE on June 2, 2017.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.